Investigation on recombinant hirudin via oral route

Add time:07/30/2019    Source:sciencedirect.com

The possibility for oral administration of peptide recombinant hirudin variant (rHV2-K47) as an anticoagulant agent was evaluated in several aspects. The proteolytic properties of rHV2-K47 and its stability during storage were examined by in vitro experiments. Radiolabeled rHV2-K47 was infused into the duodenum of rats and rHV2-K47 absorbed into serum was shown to be intact by electrophoresis pattern. The in vivo coagulation time of blood from mouse was prolonged significantly after oral administration of rHV2-K47. The bioavailability (F) of rHV2-K47 via oral route reached 10.11% in comparison with intravenous administration as gold standard. All the results suggested that rHV2-K47 could be delivered successfully via the oral route.

We also recommend Trading Suppliers and Manufacturers of hirudin HV3 (cas 134289-40-0). Pls Click Website Link as below: cas 134289-40-0 suppliers

Prev:Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: Role of recombinant hirudin variant III
Next:Potential use of hirudin in diabetic cataract: A study of galactose mediated human lens epithelial cells injury)